Conditions: Schizophrenia Schizoaffective Disorder
Keywords: Schizophrenia Lurasidone Latuda
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 149
Healthy volunteers: no

Brief summary:
Lurasidone (lurasidone HCl) is a novel psychotropic agent that is being developed as a potential new antipsychotic treatment for patients with schizophrenia. Switching between antipsychotic medications is common in the treatment of schizophrenia. The purpose of this study is to characterize the long-term safety and tolerability of lurasidone in subjects with schizophrenia or schizoaffective disorder and to allow for continued treatment for subjects completing the core study (D1050289-NCT01143077).

Detailed description:

Arms:
arm 1: Subjects will continue on treatment with the same dose of lurasidone flexible dosing - 40 mg to 12 mg once daily taken orallay at endpoint of the D1050289 ( NCT01143077) core study.

Interventions: intervention 1: Lurasidone HCl
Intervention descriptions: intervention 1: 40 mg Lurasidone tablets, 40 - 120 mg per day for up to 6 months

Protocol document: